Form 4: ACADIA PHARMACEUTICALS Director Elizabeth Garofalo Reports Routine Equity Compensation and Ownership Update

ACADIA PHARMACEUTICALS Inc. Director Elizabeth A. Garofalo reported the vesting and exercise of restricted stock units, alongside the grant of new stock options and restricted stock units, as part of her compensation.

Summary

• On May 29, 2025, Elizabeth A. Garofalo, a Director of ACADIA PHARMACEUTICALS INC. (ACAD), reported changes in her beneficial ownership of company securities.
• She acquired 9,387 shares of common stock through the vesting and exercise of previously granted restricted stock units (RSUs).
• Following this transaction, her direct beneficial ownership of common stock stands at 26,982 shares.
• Additionally, Ms. Garofalo was granted 13,793 Director Stock Options with an exercise price of $22.29 per share, which will vest quarterly over one year or until the next annual meeting.
• She also received a grant of 8,107 new Restricted Stock Units, which will vest in full on the earlier of one year from the grant date or the next annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects routine equity compensation for a director, aligning their interests with shareholders through increased ownership and future vesting awards. There are no negative implications or sales of shares beyond what might be routine tax withholding.

Positives

• The vesting and exercise of 9,387 restricted stock units into common stock increases the director's direct equity stake in the company.
• The grant of 13,793 stock options and 8,107 restricted stock units aligns the director's incentives with shareholder value creation and represents ongoing compensation for her role.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of insider equity compensation and does not provide broader insights into industry trends or competitive positioning beyond the company's standard compensation practices for its directors.

Stakeholder Impact

• Shareholders: The grant of new equity awards could lead to minor dilution over time as shares are issued upon vesting and exercise, but it also serves to align the director's interests with shareholder value.
• Director (Elizabeth A. Garofalo): Directly benefits from increased equity ownership and future compensation through stock options and restricted stock units.

Next Steps

• The newly granted stock options will vest quarterly over one year following the date of grant, or earlier upon the next annual meeting of stockholders.
• The newly granted restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.

Key Dates

Keywords

ACADIA PHARMACEUTICALS, ACAD, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership